Recent Posts

Postings by date

April 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  

Archives

Categories

Recent Comments

Meta

Medicine’s Most Infamous Clinical Trial

Study 329 had all the makings of a scandal.

Thousands of North American children and adolescents were seriously harmed by taking SSRIs like Paxil. Many died. Neither doctors nor parents had the information they needed, and the FDA only reluctantly issued the appropriate warnings, as might be expected from a regulator that has “corporate partnership” in its mandate.

End of quote.

In simple terms, a revisit of the study produced the exact opposite conclusions:

Same Data, Opposite Conclusions

Original Study 329
(2001)
Click here
Restoring Study 329
(2015)
Click here
Conclusion Paxil was effective. Paxil was not effective.
Paxil was well tolerated. Paxil caused serious side effects, including hostility, insomnia, and akathisia.
Adverse Events Did not include all Included all adverse events, including in taper phase
Suicidal behavior 6 adolescents experienced “emotionally lability” 13 adolescents became suicidal
Implications Misled doctors into prescribing a drug that is ineffective, unsafe for adolescents Corrects the record, reveals that the data did not support the conclusion of the original study

End of quote.

I suspect this phenomenon is far more common than we like to think. We are deluded if we think the FDA and their equivalents elsewhere will act in the best interests of the public. Rather, their purpose is to create the delusion that they are, when they are usually doing the exact opposite; serving Big Pharma.

Please follow and like us:

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Next Post

Agenda 2030 and the Looming "New Economic World Order"

Sun Sep 20 , 2015
This excellent article outlines the march of the global elite to fashion our future. Whilst the current event in the frame is the UN meeting […]
WP2Social Auto Publish Powered By : XYZScripts.com
RSS
Follow by Email